PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma

被引:3
|
作者
Sahinli, Hayriye [1 ]
Akyurek, Nalan [2 ]
Yilmaz, Mukaddes [3 ]
Kandemir, Olcay [4 ]
Duran, Ayse Ocak [5 ]
Kulacoglu, Sezer [6 ]
Ucar, Gokhan [7 ]
Acar, Elif [2 ]
Ozet, Ahmet [3 ]
Gumus, Mahmut [8 ]
Oksuzoglu, O. Berna C. [5 ]
Ozdemir, Nuriye Y. [7 ]
机构
[1] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Oncol, Ankara, Turkey
[2] Gazi Univ, Dept Pathol, Med Hosp, Ankara, Turkey
[3] Gazi Univ, Dept Oncol, Med Univ Hosp, Ankara, Turkey
[4] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Dept Pathol, Ankara, Turkey
[5] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Dept Oncol, Ankara, Turkey
[6] Ankara Numune Training & Res Hosp, Dept Pathol, Ankara, Turkey
[7] Ankara Numune Training & Res Hosp, Dept Oncol, Ankara, Turkey
[8] Istanbul Medipol Univ, Dept Oncol, Med Sch, Istanbul, Turkey
关键词
Nasopharyngeal carcinoma; prognosis; programmed death ligand-1; TUMOR-INFILTRATING LYMPHOCYTES; PROGRAMMED DEATH LIGAND-1; GASTRIC-CANCER; DISTINCT EXPRESSION; T-CELLS; MICROENVIRONMENT; CHEMORADIOTHERAPY; RADIOTHERAPY; SURVIVAL; PHASE;
D O I
10.4103/ijc.IJC_459_19
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Programmed death-ligand 1 (PD-L1) has been determined as a reliable prognostic factor for various malignancies. In this study, we aimed to determine the prognostic effect of PD-L1 expression in tumor-infiltrating immune cells (TIICs) of nasopharyngeal carcinoma (NPC) patients. Methods: Seventy patients diagnosed with non-metastatic NPC were included in the study. PD-L1 expression on immune cells was analyzed by immunohistochemical method. Patients were categorized into two groups according to the PD-L1 expression level in TIICs (level of PD-L1 staining >= 5% positive vs <5% negative). Results: Median follow-up period was 34 months (range = 1 - 188). 1 and 2 years survival rate were found as 75% and 63% in PD-L1 negative TIICs group (47%), and 85% and 83% in PD-L1 positive TIICs group (53%), respectively. PD-L1 positivity in immune cells (ICs) was detected in 53% of the patients. The survival rate was found better in the PD- L1 positive group compared to the negative group (P = 0.049). Discussion: In conclusion, the survival rate was found significantly better in the PD-L1 positive TIICs group, compared to the negative group.
引用
收藏
页码:561 / 566
页数:6
相关论文
共 50 条
  • [1] High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma
    Zhong, Qiaofeng
    Shou, Jianzhong
    Ying, Jianming
    Ling, Yun
    Yu, Yue
    Shen, Zhirong
    Zhang, Yun
    Li, Ning
    Shi, Yuankai
    Zhou, Aiping
    FUTURE ONCOLOGY, 2021, 17 (22) : 2893 - 2905
  • [2] PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients
    Sznurkowski, Jacek J.
    Zawrocki, Anton
    Sznurkowska, Katarzyna
    Peksa, Rafal
    Biernat, Wojciech
    ONCOTARGET, 2017, 8 (52): : 89903 - 89912
  • [3] PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma
    Mocan, Lavinia Patricia
    Craciun, Rares
    Grapa, Cristiana
    Melincovici, Carmen Stanca
    Rusu, Ioana
    Al Hajjar, Nadim
    Sparchez, Zeno
    Leucuta, Daniel
    Ilies, Maria
    Sparchez, Mihaela
    Mocan, Tudor
    Mihu, Carmen Mihaela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (04) : 1003 - 1014
  • [4] PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma
    Lavinia Patricia Mocan
    Rares Craciun
    Cristiana Grapa
    Carmen Stanca Melincovici
    Ioana Rusu
    Nadim Al Hajjar
    Zeno Sparchez
    Daniel Leucuta
    Maria Ilies
    Mihaela Sparchez
    Tudor Mocan
    Carmen Mihaela Mihu
    Cancer Immunology, Immunotherapy, 2023, 72 : 1003 - 1014
  • [5] PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
    Kim, Hye Ryun
    Ha, Sang-Jun
    Hong, Min Hee
    Heo, Su Jin
    Koh, Yoon Woo
    Choi, Eun Chang
    Kim, Eun Kyung
    Pyo, Kyoung Ho
    Jung, Inkyung
    Seo, Daekwan
    Choi, Jaewoo
    Cho, Byoung Chul
    Yoon, Sun Och
    SCIENTIFIC REPORTS, 2016, 6
  • [6] PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
    Hye Ryun Kim
    Sang-Jun Ha
    Min Hee Hong
    Su Jin Heo
    Yoon Woo Koh
    Eun Chang Choi
    Eun Kyung Kim
    Kyoung Ho Pyo
    Inkyung Jung
    Daekwan Seo
    Jaewoo Choi
    Byoung Chul Cho
    Sun Och Yoon
    Scientific Reports, 6
  • [7] PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma
    Sughayer, Maher A.
    Dabbagh, Tamara Z.
    Battah, Abdelkader H.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (10) : 748 - 754
  • [8] PD-L1 Expression is an Unfavorable Prognostic Factor in Hepatocellular Carcinoma
    Baek, M.
    Jung, H.
    Ahn, T.
    Park, S.
    Bae, S.
    Jung, D.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S111 - S111
  • [9] PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
    Cooper, Wendy A.
    Thang Tran
    Vilain, Ricardo E.
    Madore, Jason
    Selinger, Christina I.
    Kohonen-Corish, Maija
    Yip, PoYee
    Yu, Bing
    O'Toole, Sandra A.
    McCaughan, Brian C.
    Yearley, Jennifer H.
    Horvath, Lisa G.
    Kao, Steven
    Boyer, Michael
    Scolyer, Richard A.
    LUNG CANCER, 2015, 89 (02) : 181 - 188
  • [10] The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma
    Guenole, Morgan
    Benigni, Paolo
    Bourbonne, Vincent
    Lucia, Francois
    Legoupil, Delphine
    Pradier, Olivier
    Misery, Laurent
    Uguen, Arnaud
    Schick, Ulrike
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2569 - 2578